Addex Therapeutics
ADXN
4 hedge funds and large institutions have $2.86K invested in Addex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
39% less capital invested
Capital invested by funds: $4.71K → $2.86K (-$1.85K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $1.89K | +$7 | +1 | +0.3% |
|
|
GI
2
GAMMA Investing
Foster City,
California
| $509 | – | – | – |
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $450 | – | – | – |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $6 | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$1.2K | -156 | Closed |
|
ADXN Hedge Fund Activity: Q1 2026 in Review
4 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q1 2026, worth a combined $2.86K — down 39% from $4.71K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ADXN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $7. The largest seller was UBS Group, exiting entirely with an estimated $1.2K sold.
- 4 institutional investors held Addex Therapeutics (ADXN) as of Q1 2026, down from 5 in Q4 2025.
- Funds reported $2.86K of Addex Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
- 0 funds opened new Addex Therapeutics positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Addex Therapeutics buyer in Q1 2026 was Morgan Stanley, an estimated $7 added.
- The largest Addex Therapeutics seller in Q1 2026 was UBS Group, an estimated $1.2K sold.
Based on aggregated 13F filings for Q1 2026.